MIRAPEX ER
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Mar 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MIRAPEX ER is an extended-release oral tablet approved in 2010 by Boehringer Ingelheim as a small-molecule therapeutic. The specific indication and mechanism of action are not disclosed in available data, limiting clinical context for career positioning.
$0.794MPart D
LOE ApproachingLOE-approaching lifecycle with minimal Part D claims (494 in 2023) signals a small-scale, mature product with limited growth opportunities and likely lean commercial infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MIRAPEX ER currently shows zero linked job postings, reflecting its mature, low-volume commercial footprint and impending LOE. Roles on this product focus on maintaining market share and managing generic transition rather than growth-oriented activities.
Brand ManagerField Sales Representative
Worked on MIRAPEX ER at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.